John Fung to Interferon-alpha
This is a "connection" page, showing publications John Fung has written about Interferon-alpha.
Connection Strength
0.200
-
Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl. 2002 Nov; 8(11):1007-13.
Score: 0.052
-
Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl. 2001 Oct; 7(10):863-9.
Score: 0.048
-
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 1998 Jan 15; 65(1):82-6.
Score: 0.037
-
Liver transplantation for hepatitis B: what have we learned and what does the future hold? Liver Transpl Surg. 1995 Jul; 1(4):274-80.
Score: 0.031
-
Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients. Liver Transpl. 2009 Nov; 15(11):1557-63.
Score: 0.021
-
Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation. 1997 Aug 15; 64(3):422-6.
Score: 0.009